Ad
related to: editas medicine
Search results
Results From The WOW.Com Content Network
Editas Medicine, Inc., (formerly Gengine, Inc.), is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. [ 2 ] [ 3 ] Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado .
After another solid quarter of progress, the genome-editing company looks forward to a phase 1/2 study for its revolutionary CRISPR medicine. Editas Medicine Prepares to Make History With EDIT-101 ...
Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines.
Editas (EDIT) focuses on the development of its lead candidate, EDIT-101, for treating LCA10, a rare genetic illness that causes blindness. Excessive reliance on partners for revenues remains a woe.
Editas (EDIT) doses the first patient pediatric patient in the BRILLIANCE study on EDIT-101 for treating Leber congenital amaurosis 10 (LCA10).
J. Keith Joung is an American pathologist and molecular biologist who holds the Robert B. Colvin Endowed Chair in Pathology [1] at Massachusetts General Hospital and is Professor of Pathology at Harvard Medical School. [2]
Editas Medicine is a discovery-phase pharmaceutical company based in Cambridge, Massachusetts, which aims to develop therapies based on CRISPR–Cas9 gene editing technology. [2] to Editas Medicine is a clinical-stage biotechnology company based in Cambridge, Massachusetts, which is developing therapies based on CRISPR–Cas9 gene editing ...
Editas (EDIT) progresses well with the development of its lead candidate, EDIT-101, to treat LCA10, a rare genetic illness that causes blindness. Dependence on partners for revenues is a concern.